SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/15 – ‘EX-12.B’

On:  Wednesday, 3/30/16, at 9:42pm ET   ·   As of:  3/31/16   ·   For:  12/31/15   ·   Accession #:  1176256-16-495   ·   File #:  1-12033

Previous ‘20-F’:  ‘20-F’ on 3/31/15 for 12/31/14   ·   Next:  ‘20-F’ on 3/31/17 for 12/31/16   ·   Latest:  ‘20-F’ on 5/2/23 for 12/31/22   ·   4 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/31/16  Nymox Pharmaceutical Corp         20-F       12/31/15    8:1.2M                                   e3 Fil… Computershare/FA

Annual Report by a Foreign Private Issuer   —   Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report for the Fiscal Year Ended December    HTML    836K 
                          31, 2015                                               
 2: EX-4.W      Common Stock Private Purchase Agreement Dated       HTML    105K 
                          November 1, 2013                                       
 3: EX-4.X      6% Secured Convertible Note Dated December 16,      HTML     54K 
                          2014                                                   
 4: EX-4.Y      Response Letter From Kpmg in the Corporation's 6-K  HTML     31K 
                          Dated July 16, 2015                                    
 7: EX-13.A     Sox Section 906 CEO Certification                   HTML      7K 
 8: EX-13.B     Sox Section 906 CFO Certification                   HTML      7K 
 5: EX-12.A     Sox Section 302 CEO Certification                   HTML     11K 
 6: EX-12.B     Sox Section 302 CFO Certification                   HTML     12K 


EX-12.B   —   Sox Section 302 CFO Certification


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Exhibit 12 (a)  

Exhibit 12 (b)


CERTIFICATION

I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that:

1.

I have reviewed this annual report for the period ended December 31, 2015 of Nymox Pharmaceutical Corporation;

 

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

 

 

4.

The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)), and internal control over financial reporting (as defined in the Exchange Act Rules 13a–15(f) and 15d–15(f)) for the company based on the COSO 1992 framework and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with international financial reporting standards;

c) evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5.

The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: March 30, 2016

/s/ Erik Danielsen
Erik Danielsen
Chief Financial Officer
Nymox Pharmaceutical Corporation




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘20-F’ Filing    Date    Other Filings
Filed as of:3/31/166-K
Filed on:3/30/16
For Period End:12/31/156-K,  6-K/A
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/30/22  Nymox Pharmaceutical Corp.        20-F       12/31/21  106:6M                                     Pubco Reporting … Inc/FA
 3/29/21  Nymox Pharmaceutical Corp.        20-F       12/31/20  103:4.4M                                   Pubco Reporting … Inc/FA
11/01/16  SEC                               UPLOAD9/27/17    1:126K Nymox Pharmaceutical Corp.
 9/21/16  SEC                               UPLOAD9/27/17    1:153K Nymox Pharmaceutical Corp.
Top
Filing Submission 0001176256-16-000495   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 1:13:06.1am ET